9/5/2019 8:07:24 AM
OncoCyte Enters Definitive Agreement To Acquire Razor Genomics
6/26/2019 9:07:09 AM
OncoCyte Requires Addl Time To Complete Ongoing CLIA Validation Study Of DetermaVu, Liquid Biopsy Test For Lung Cancer
6/6/2019 6:36:04 AM
OncoCyte Appoints Current Board Member Ronald Andrews As CEO, Effective July 1
2/8/2019 9:02:58 AM
OncoCyte Prices Public Offering Of 9.33 Mln Shares At $3.75 Per Share
1/29/2019 7:18:48 AM
OncoCyte Says Positive Results From Key R&D Validation Study Demonstrating Accuracy Of DetermaVu Liquid Biopsy Test
11/8/2018 6:49:54 AM
BioTime Q3 Net Income $66.7 Mln Or $0.53/shr Vs. $14.3 Mln Or $0.12/shr Last Year
11/8/2018 6:39:47 AM
BioTime To Acquire All Remaining Outstanding Common Stock Of Asterias
9/18/2018 7:00:36 AM
BioTime Implements New Leadership Structure; Appoints Brian Culley As CEO
9/17/2018 1:01:00 AM
BioTime Updates Timeline For Distribution Of AgeX Shares To BioTime Shareholders
8/16/2018 8:03:46 AM
AgeX Therapeutics Acquires Certain Patents And Patent Applications From Escape Therapeutics
8/14/2018 4:12:27 PM
OncoCyte Corp. Q2 Loss/share $0.12 Vs. Loss $0.13 Year Ago
8/2/2018 8:08:09 AM
BioTime Announces New Strategic Alignment Between AgeX Therapeutics And Juvenescence
6/29/2018 7:04:19 AM
BioTime Secures Grant From The National Institutes Of Health
6/11/2018 7:00:57 AM
AgeX Therapeutics Closes On $5 Mln Strategic Investment From Juvenescence